MicroRNA-98: the multifaceted regulator in human cancer progression and therapy
Cancer Cell International · 13.06.2024 · 24 (1)
DOI: 10.1186/s12935-024-03386-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Cell International, online erschienen am 13.06.2024. Verfasst von Vajihe Hazari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, School of Medicine, Rooyesh Infertility Center, Birjand University of Medical Sciences, Birjand, Iran. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
MicroRNA-98 ( miR-98 ) stands as an important molecule in the intricate landscape of oncology. As a subset of microRNAs, these small non-coding RNAs have accompanied a new era in cancer research, underpinning their significant roles in tumorigenesis, metastasis, and therapeutic interventions. This review provides a comprehensive insight into the biogenesis, molecular properties, and physiological undertakings of miR-98 , highlighting its double-edged role in cancer progression—acting both as a tumor promoter and suppressor. Intriguingly, miR-98 has profound implications for various aspects of cancer progression, modulating key cellular functions, including proliferation, apoptosis, and the cell cycle. Given its expression patterns, the potential of miR-98 as a diagnostic and prognostic biomarker, especially in liquid biopsies and tumor tissues, is explored, emphasizing the hurdles in translating these findings clinically. The review concludes by evaluating therapeutic avenues to modulate miR-98 expression, addressing the challenges in therapy resistance, and assessing the efficacy of miR-98 interventions. In conclusion, while miR-98 ’s involvement in cancer showcases promising diagnostic and therapeutic avenues, future research should pivot towards understanding its role in tumor-stroma interactions, immune modulation, and metabolic regulation, thereby unlocking novel strategies for cancer management. Graphical Abstract
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, School of Medicine, Rooyesh Infertility Center, Birjand University of Medical Sciences, Birjand, Iran.
- Department of Microbiology, Yasooj Branch, Islamic Azad University, Yasooj, Iran.
- Reza Radiotherapy and Oncology Center, Mashhad, Iran.
- Department of Biology, Faculty of Sciences, University of Birjand, Birjand, Iran.
- Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran. f.sadri87@yahoo.com.
- Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran. f.sadri87@yahoo.com.
Zitieren
APA
Hazari, V., Samali, S. A., Izadpanahi, P., Mollaei, H., Sadri, F., & Rezaei, Z. (2024). MicroRNA-98: the multifaceted regulator in human cancer progression and therapy. Cancer Cell International, 24(1). https://doi.org/10.1186/s12935-024-03386-2
Vancouver
Hazari V, Samali SA, Izadpanahi P, Mollaei H, Sadri F, Rezaei Z. MicroRNA-98: the multifaceted regulator in human cancer progression and therapy. Cancer Cell International. 2024;24(1). doi:10.1186/s12935-024-03386-2
BibTeX
@article{Hazari2024,
author = {Hazari, Vajihe and Samali, Sahar Ahmad and Izadpanahi, Payam and Mollaei, Homa and Sadri, Farzad and Rezaei, Zohreh},
title = {MicroRNA-98: the multifaceted regulator in human cancer progression and therapy},
journal = {Cancer Cell International},
year = {2024},
volume = {24},
number = {1},
doi = {10.1186/s12935-024-03386-2}
}
EUVIMED